Welcome to our dedicated page for Microbix Biosys news (Ticker: MBXBF), a resource for investors and traders seeking the latest updates and insights on Microbix Biosys stock.
Microbix Biosystems Inc. (MBXBF) is a life sciences innovator, manufacturer, and exporter that focuses on biological products for the global diagnostics industry. News about Microbix often centers on developments in its antigen manufacturing capabilities, expansion of its quality assessment products (QAPs™), and updates on its reference materials (QUANTDx™) used by clinical laboratories and diagnostics makers.
Investors and industry professionals following Microbix news can expect updates on product commercialization, such as the company’s recombinant nucleocapsid antigen of the SARS-CoV-2 virus for use in QAPs and by test manufacturers. Coverage may also include announcements related to its expertise in native viral antigens, new applications of its QAPs and reference materials in proficiency testing and external quality assessment programs, and developments in reagents and media that support diagnostic testing, including DxTM™ for patient-sample collection.
Microbix news releases also address regulatory and disclosure matters, including interactions with securities regulators about continuous disclosure practices and the use of non-IFRS financial measures. These items provide context about how the company presents its financial and operational information to investors.
Because Microbix supplies antigens to approximately 100 diagnostics makers and distributes QAPs in over 30 countries, its news can be relevant to stakeholders across the diagnostics value chain. By monitoring this page, readers can review announcements about product launches, manufacturing capabilities, quality and regulatory accreditations, and other corporate communications that shape the company’s role in the diagnostics and life sciences sectors.
Microbix (OTCQX:MBXBF, TSX:MBX) is releasing three episodes of season two of its podcast Diagnostics: Beyond the Lab on April 20, 2026. Hosted by CEO Cameron Groome, each ~60-minute episode features diagnostics experts discussing adoption, quality assessment, and community engagement.
Guests include James Yantzi (Seegene Canada), Dr. Simon Patton (EMQN), and Dr. Tanya Applegate with Stacey Foster-Rampant (Kirby Institute). Episodes are available this spring on microbix.com and major podcast platforms; season one remains accessible via the same links.
Microbix (OTCQX:MBXBF, TSX:MBX) will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21–22, 2026. COO Dr. Ken Hughes will present in person on April 22 at 2:00 p.m. ET and the management team will hold one-on-one investor meetings. Presentation slides will be available for download at the company website.
Microbix (OTCQX:MBXBF) will exhibit and present at ESCMID Global 2026 (April 17–21, Munich), showcasing its QAP™ whole-process quality controls for RNA-based assays and QUANTDx quantified reference materials.
Microbix will present a poster on a non-infectious phage-encapsulated RNA HCV mimetic validated as a safe, stable, whole-process control.
Microbix (OTCQB:MBXBF / TSX:MBX) reported results from its Annual Meeting held March 25, 2026, with 27.44% of issued shares represented.
All resolutions passed; all board nominees were re-elected. Notable vote results: Jennifer Stewart received 86.07% support (13.93% withheld). Auditors Ernst & Young LLP were re-appointed with 96.66% support. Meeting materials and slides are posted on the company website and SEDAR+.
Microbix (OTCQX:MBXBF, TSX:MBX) will present QUANTDx reference-material innovations at EUROGIN in Vienna, March 18–21, 2026. The Poster describes normalized HPV viral loads—viral genome counts expressed per human cell—to improve assay validation and sample-adequacy interpretation.
QUANTDx offers >80 quantified, traceable materials across six infectious-disease panels to support LoD, sensitivity, and specificity testing and enable validation of new sample formats such as first-void urine and self-collected swabs.
Microbix (OTCQX:MBXBF) announced that a CDMO engaged by funding partner Sequel Pharma has modernized production methods for the Drug Substance of Kinlytic urokinase to reduce animal‑origin inputs. Work is progressing toward an sBLA and has moved into formulation, fill and finish Drug Product phases.
The company reiterated a targeted timeline of calendar 2028 for reintroduction in the U.S. for catheter clearance and said further manufacturing, clinical, regulatory, or commercial milestones may be disclosed when meaningful.
Microbix (TSX:MBX / OTCQX:MBXBF) announced the issuance of 2,600,000 stock options under its shareholder-approved Stock Option Plan on February 24, 2026. Options are exercisable at $0.23 per share, vest after three years, and expire after five years; grants are subject to TSX approval.
The awards span 37 senior employees and directors, with a quarterly expense estimate of $24,000 (≈2% of total compensation). Potential dilution is stated as up to 2% of issued shares, partly offset by ~600,000 shares repurchased under a normal-course issuer bid started December 2025.
Microbix (OTCQX:MBXBF) reported Q1 fiscal 2026 results for the quarter ended December 31, 2025, with revenue of $4.22M (down 30% YoY, up 13% QoQ) and a net loss of $1.17M. Gross margin fell to 41% from 62% a year earlier. Cash was $9.10M and accounts receivable rose to $3.98M. Management expects full‑year results in line with disclosed forward‑looking information and is pursuing new clients and programs; a Q1 webinar is scheduled for February 12, 2026 at 10:00 AM ET.
Microbix (OTCQX:MBXBF) has begun supplying its quality assessment products (QAPs) to the College of American Pathologists (CAP) to support CAP proficiency-testing (PT/EQA) programs as of February 10, 2026. Multiple QAP SKUs have been provided under customary supply and quality agreements, and Microbix plans expansion through fiscal 2026.
The QAPs are designed to emulate patient specimens while remaining safe and stable, supporting diagnostic workflows and ISO 17043-certified PT/EQA programs.
Microbix (OTCQX:MBXBF, TSX:MBX) will release financial results for its first quarter of fiscal 2026 (period ended December 31, 2025) prior to market open on February 12, 2026. A live webinar discussion with CEO, CFO and COO is scheduled for 10:00 AM ET that day and will be hosted by Adelaide Capital.
Investors can register via Zoom and watch a YouTube livestream; a replay will be posted on Adelaide Capital's YouTube channel.